Viral Growth | Business Facilities - Area Economic Development, Site Selection & Workforce Solutions

From the Desk of the Editor in Chief


https://businessfacilities.com/2009/05/viral-growth/
From the Desk of the Editor in Chief
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Viral Growth

Viral Growth | Business Facilities - Area Economic Development, Site Selection & Workforce Solutions

From the Desk of the Editor in Chief

Contagion is on everybody’s mind these days. The banking system remains in intensive care, the credit markets have flatlined, and the economy is slowly, painfully being nursed back to health with massive injections of government triage.

As this issue of Business Facilities goes to press, a lurking physical menace has overshadowed even the pervasive fiscal malaise. A new flu virus reared its invisible head in Mexico and now threatens to explode into a global pandemic.

We didn’t plan it this way, but all of the attention being paid to sickness and health happens to coincide with our annual look at the biotechnology industry.

Like every other sector of the ailing economy, biotech has taken a hit from the financial squeeze. Smaller start-ups that depend on infusions of cash to carry them through the lengthy development cycle for new drugs are finding their lifelines cut off.

But while some consolidation may be inevitable, the overall trend is positive. We are pleased to report that numerous states have resisted the temptation to trim their investments in long-term biotech initiatives as an easy fix for budget deficits. Others are “doubling down” on their bets that biotech soon will emerge as a leading industry of the 21st century.

The long-term prognosis calls for “viral growth” in biotech: the global market is expected to grow threefold in the coming decade, exceeding $120 billion.

Now that’s an outbreak worth cheering about.

Jack Rogers
[email protected]

Suggested Links:

You Might Like:

  • Building A Biotech ReboundA slow start and a dearth of mergers and acquisitions made 2016 a tough year for biotech, but new gene and immuno-therapies are leading the way for a much stronger performance when 2017 results are in.
  • Anthem Bringing Over 1,800 Jobs To AtlantaThe health benefits company will invest $20M to expand its presence in Georgia with an Information Technology Hub.
  • Geek SquadA 22-year-old programmer stops a global cyber attack by purchasing an unregistered domain name for $10.69.
SHARE
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Previous articleWorst, er, Best Idea of the Week: No Blagojevich!
Next article60 Seconds with Alex Brigham, Executive Director, Ethisphere Institute

LEAVE A REPLY